Russell Investments Group’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $127K | Buy |
171,809
+171,629
| +95,349% | +$132K | ﹤0.01% | 3397 |
|
|
2026
Q2 | $148 | Sell |
180
-21,454
| -99% | -$20.3K | ﹤0.01% | 4252 |
|
|
2026
Q1 | $19.9K | Sell |
21,634
-3,504
| -14% | -$4.24K | ﹤0.01% | 3624 |
|
|
2025
Q4 | $32.2K | Buy |
25,138
+117
| +0.5% | +$157 | ﹤0.01% | 3466 |
|
|
2025
Q3 | $32.5K | Buy |
25,021
+24,211
| +2,989% | +$31.7K | ﹤0.01% | 3434 |
|
|
2025
Q2 | $972 | Buy |
+810
| New | +$898 | ﹤0.01% | 3671 |
|
|
2025
Q1 | – | Sell |
-220
| Closed | -$385 | – | 3840 |
|
|
2024
Q4 | $385 | Hold |
220
| – | – | ﹤0.01% | 3633 |
|
|
2024
Q3 | $425 | Hold |
220
| – | – | ﹤0.01% | 3585 |
|
|
2024
Q2 | $389 | Hold |
220
| – | – | ﹤0.01% | 3518 |
|
|
2024
Q1 | $596 | Buy |
+220
| New | +$531 | ﹤0.01% | 3186 |
|
|
2020
Q4 | – | Sell |
-106,289
| Closed | -$788K | – | 3125 |
|
|
2020
Q3 | $788K | Sell |
106,289
-1,324,628
| -93% | -$9.14M | ﹤0.01% | 2169 |
|
|
2020
Q2 | $5.74M | Sell |
1,430,917
-5,840,328
| -80% | -$20.3M | 0.01% | 1019 |
|
|
2020
Q1 | $18.5M | Buy |
7,271,245
+1,411,413
| +24% | +$4.64M | 0.05% | 430 |
|
|
2019
Q4 | $20.4M | Buy |
5,859,832
+1,850,282
| +46% | +$6.51M | 0.04% | 536 |
|
|
2019
Q3 | $18.6M | Sell |
4,009,550
-1,428,479
| -26% | -$11.3M | 0.04% | 568 |
|
|
2019
Q2 | $67M | Sell |
5,438,029
-149,060
| -3% | -$1.9M | 0.13% | 192 |
|
|
2019
Q1 | $74.2M | Buy |
5,587,089
+423,877
| +8% | +$4.47M | 0.14% | 164 |
|
|
2018
Q4 | $44.5M | Buy |
5,163,212
+889,727
| +21% | +$6.93M | 0.1% | 231 |
|
|
2018
Q3 | $32M | Sell |
4,273,485
-121,465
| -3% | -$863K | 0.06% | 366 |
|
|
2018
Q2 | $26.2M | Buy |
4,394,950
+684,781
| +18% | +$3.9M | 0.05% | 417 |
|
|
2018
Q1 | $21.7M | Sell |
3,710,169
-121,070
| -3% | -$795K | 0.04% | 574 |
|
|
2017
Q4 | $23.6M | Buy |
3,831,239
+383,748
| +11% | +$2.1M | 0.04% | 565 |
|
|
2017
Q3 | $17.4M | Buy |
3,447,491
+1,099,072
| +47% | +$4.62M | 0.03% | 693 |
|
|
2017
Q2 | $9.48M | Buy |
2,348,419
+89,482
| +4% | +$424K | 0.02% | 942 |
|
|
2017
Q1 | $12.8M | Buy |
2,258,937
+19,725
| +0.9% | +$125K | 0.02% | 745 |
|
|
2016
Q4 | $16.1M | Buy |
2,239,212
+540,558
| +32% | +$3.39M | 0.03% | 641 |
|
|
2016
Q3 | $13.6M | Buy |
1,698,654
+256,837
| +18% | +$2.36M | 0.03% | 707 |
|
|
2016
Q2 | $13M | Buy |
1,441,817
+309,540
| +27% | +$2.91M | 0.02% | 802 |
|
|
2016
Q1 | $9.14M | Buy |
+1,132,277
| New | +$8.17M | 0.02% | 1001 |
|
|
2015
Q2 | – | Sell |
-300,771
| Closed | -$12.7M | – | 3058 |
|
|
2015
Q1 | $12.7M | Buy |
300,771
+67,652
| +29% | +$2.67M | 0.02% | 775 |
|
|
2014
Q4 | $7.82M | Sell |
233,119
-988
| -0.4% | -$28K | 0.01% | 1014 |
|
|
2014
Q3 | $5.74M | Buy |
234,107
+33,052
| +16% | +$929K | 0.01% | 1198 |
|
|
2014
Q2 | $5.91M | Buy |
201,055
+65,105
| +48% | +$2.09M | 0.01% | 1219 |
|
|
2014
Q1 | $4.9M | Buy |
135,950
+7,795
| +6% | +$343K | 0.01% | 1315 |
|
|
2013
Q4 | $5.44M | Buy |
128,155
+3,505
| +3% | +$103K | 0.01% | 1177 |
|
|
2013
Q3 | $2.8M | Buy |
124,650
+124,495
| +80,319% | +$2.45M | ﹤0.01% | 1676 |
|
|
2013
Q2 | $3K | Hold |
155
| – | – | ﹤0.01% | 3149 |
|
Other funds holding LAB
LFCM
Russell Investments Group's LAB Position: Q3 2026 in Review
Russell Investments Group increased its Standard BioTools (LAB) stake by 95,349% in Q3 2026, buying an estimated $132K and bringing the position to 171,809 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #3397.
Russell Investments Group first reported a position in LAB in Q2 2013 and has held it in 37 quarters since. The position peaked at $74.2M in Q1 2019. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.
- Russell Investments Group held 171,809 shares of Standard BioTools worth $127K as of Q3 2026.
- Russell Investments Group bought 171,629 Standard BioTools shares in Q3 2026, an estimated $132K.
- Standard BioTools made up ﹤0.01% of Russell Investments Group's portfolio in Q3 2026, its #3397 holding.
- Russell Investments Group first reported a position in Standard BioTools in Q2 2013 and has held it in 37 quarters since.
- Russell Investments Group's Standard BioTools position peaked at $74.2M in Q1 2019.
- 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.
Based on Russell Investments Group's 13F filing for Q3 2026, filed 6 Nov 2026.